Clinical Use of Hormones in the Control of Reproduction in Bitches and Queens
WSAVA 2002 Congress
Prof. Stefano Romagnoli, DVM, MS, PhD, Dipl ECAR
Dipartimento di Scienze Cliniche Veterinarie, Facoltà di Medicina Veterinaria, Università di Padova
Legnaro (PD), Italia
stefano.romagnoli@unipd.it
P: 39-049-827.2948
F: 827.2954

Introduction

Synthetic analogues of progesterone, also termed progestins or progestogens (PG), are pharmaceutical compounds commonly used to control the reproductive cycle of domestic animals The following PGs are commonly used in dogs and cats for temporary (starting the treatment shortly before proestrus onset) or prolonged (starting in anestrus) postponement of estrus, or for suppression of estrus (starting the treatment after proestrus onset): medroxyprogesterone acetate (MPA), megestrol acetate (MA), proligestone (PR), chlormadinone acetate (CMA), delmadinone acetate (DMA), norethisterone acetate (NTA) and melengestrol acetate (MGA). From the clinical point of view all these product act in the same way through a block of the production and/or release of GnRH from the hypothalamus. These compounds show a variety of action on the reproductive and endocrine system (such as hyperplasia of the endometrium, hyperplasia of the mammary parenchyma, decreased production of adrenocorticosteroids, increased secretion of prolactin and growth hormone, insulin resistance) as well as some local skin reactions at the injection site and behavioral modification (increased appetite and weight, polydipsia, slight depression, decreased libido in males). In pregnant bitches and queens use of PGs may cause masculinization of female fetuses if administered early in pregnancy (during organogenesis) or delayed parturition if administered in the last decade of pregnancy.

Clinical considerations for a safe use of progestogens

All the above cited effects are reversible and do not generally cause problems in healthy young to adult animals treated for not too long and using the recommended dosage. In general, a treatment period of 6 months is considered adequate in most individuals, although longer treatments can also be safe provided that the female is given a rest of 1-2 months every 4-6 months. While most bitches and queens may tolerate well treatment periods of more than 6 months, animals with a pre-existing disease such as subclinical diabetes, microscopic mammary lesion/tumor or cystic endometrial hyperplasia may see their condition worsen rapidly as a result of the PG treatment. The following is a series of considerations on patient selection and type of presenting complaint for which a PG treatment should or should not be used.

 Do not use long acting compounds (such as MPA or PR or any other compound marketed for long term use) prior to puberty in felines, as this may cause the queen to develop a long-lasting mammary hypertrophy which could become a life-threatening situation. In prepuberal animals it is best to use initially a short acting compound (such as MA) per os for 1-2 weeks and then change to a long acting PG once potential side effects have been ruled out.

 Do not treat pregnant females, as this may cause fetal developmental defects as well as delayed parturition, thereby causing fetal death in utero due to placental ageing and detachment.

 Do not treat pseudopregnant bitches. During a PG treatment clinical signs of pseudopregnancy will disappear but will recur once treatment is discontinued, and the problem may worsen.

 Do not treat a female during diestrus. The stage of the reproductive cycle should always be identified using vaginal cytology and/or serum progesterone assay, and the bitch or queen should best be treated during anestrus. Diestrus should be ruled out in felines too, as approximately 30% of queens ovulate spontaneously, maintaining thereafter a 30-45 day-long diestrus.

 Do not treat females with uterine haemorrhage. Prolonged sanguineous vulvar discharge following parturition in the bitch can be a critical problem which should either be treated with a uterine contractive drug (i.e., as ergonovine) or sent to surgery. Milder bloody vulvar discharge can be caused by uterine neoplasia, cystic endometrial hyperplasia with superimposed endometrial inflammation, pyometra, metritis. None of these conditions will benefit from administration of a progestogen.

 Do not treat diabetic patients. Although not always necessary, it would be wise to measure blood glucose before and/or after a prolonged treatment to confirm health status with regard to glucose metabolism.

 Do not use PGs in females with prolonged heat. A prolonged heat may be due to ovarian cyst(s), a granulosa cell tumor, or may be due to a split heat (in the bitch) or to a misinterpretation of normal estrous signs by the owner. For none of these categories is a progestogen treatment indicated (although in some cases an ovarian cyst may benefit from administration of a progestogen). Therefore, bitches or queens with a prolonged heat should not be treated with a progestogen, unless a diagnosis of cystic ovarian disease has been carefully confirmed and surgery or administration of GnRH or hCG are not a valid therapeutic option.

Choosing the right candidate

The ideal candidate is an adult postpuberal female in anestrus. Prepuberal females should not be treated long acting compounds because of the risk of precipitating a subclinical uterine, endocrine or mammary condition (such as diabetes, cystic endometrial hyperplasia-pyometra in the bitch or mammary hyperplasia in the queen) which are rare but have been reported in young animals. If one of the above conditions is present the administration of a long acting progestogen prior to diagnosis may pose a serious health threat on the female. A minimum database of clinical information to be gathered prior to administering a long-acting compound should include:

 Collecting a thorough reproductive history to rule out occurrence of estrus within the last 1-2 months (which would mean that the female is in diestrus);

 A complete clinical exam;

 Palpation of the mammary gland to rule out presence of mammary nodules;

 A vaginal smear to rule out presence of oestrus.

Table 1. Shows the suggested dosages of the most commonly used progestogen-based compounds in the bitch and queen.

Suggested Dosage

Dog

Cat

Medroxyprogesterone Acetate

2.5-3.0 mg/kg IM every 5 months

2.0 mg/kg IM every 5 months for the feline

Megestrol Acetate

<2.0 mg/kg administered for <2 weeks in proestrus, or <2.0 mg/kg administered for a longer duration of time in anestrus. A typical dosage for estrus suppression is 2.0 mg/kg/day for 8 consecutive days, while a typical dosage for temporary postponement is 0.5 mg/kg/day in late anestrus.

<5.0 mg/cat administered every other day for <3 weeks or with a slower rate of administration.

Proligestone

10-33 mg/kg SC every 3,4,5,5 months

10 mg/kg SC every 3,4,5,5, months

References

1.  Concannon PW, Hodgson B, Lein D: Reflex LH release in estrous cats following single and multiple copulations. Biol Reprod 23:111-117, 1980

2.  Curtis EM, Grant RP-Masculinization of female pups by progestogens. JAVMA 144: 395-398, 1964

3.  Dow C-The cystic hyperplasia-pyometra complex in the bitch. Vet Rec 69:1409-1415, 1957

4.  Eigenmann JE, Eigenmann RY, Rijnberk A, Van der Gaag I, Zapf J, Foesch ER-Progesterone-controlled growth hormone overproduction and naturally occurring canine diabetes and acromegaly Acta Endocrinologica 104:167-176, 1983

5.  Kooistra HS, Okkens AC, Mol JA, van Garderen E, Kirpensteijn J, Rijnberk A-Lack of association of progestin-induced cystic endometrial hyperplasia with GH gene expression in the canine uterus. Journal of Reproduction and Fertility Suppl 51: 355-361, 1997

6.  Evans JM, Sutton DJ-The use of hormones, especially progestagens, to control oestrus in bitches. J Reprod Fert Suppl 39:163-173, 1989

7.  Kooistra, Voorhout, Selman & Rijnberk: Progestin-induced GH production in the treatment of dogs with congenital GH deficiency. Dom An Endocr 15:93-102, 1998

8.  Mansfield PD, Kemppainen RJ, Sartin JL-The effects of megestrol acetate treatment on plasma glucose concentration and insulin response to glucose administration in cats. JAAHA 22: 515-518, 1986

9.  Misdorp W-Canine mammary tumors: protective effect of late ovariectomy and stimulating effect of progestins. The Vet Quarterly 10:26-33, 1988

10. Neill Johnson A - Comparative aspects of contraceptive steroids - Effects observd in beagle dogs. Toxicologic pathology 1998, 17 (2): 389-395

11. Scott DW, Concannon PW-Gross and microscopic changes in the skin of dogs with progestagen-induced acromegaly and elevated growth hormone levels. JAAHA 19:523-527, 1983

12. Selman PJ, Mol JA, Rutteman GR, Rijnberg A-Progestins and growth hormone excess in the dog. Acta Endocrinologica 125 (Suppl 1) 42, 1991

13. Shille VM, Lundstrom KE, Stabendfeldt GM: Follicular function in the domestic cat as determined by estradiol 17b concentrations in plasma: relation to estrous behaviour and cornification of exfoliated vaginal epithelium. Biol Reprod 6:953-963, 1979

14. Van den Broek AHM, O'Farrel VO-Suppression of adrenocortical function in dogs receiving therapeutic doses of megestrol acetate. J Small Anim Pract 35:285-288, 1994.

15. Van Os JL, Oldenkamp EP-Oestrus control in bitches with proligestone, a new progestational steroid. J Small Anim Practice 19: 521-529, 1978

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Stefano Romagnoli, DVM, MS, PhD, Dipl ECAR
Dipartimento di Scienze Cliniche Veterinarie
Facoltà di Medicina Veterinaria
Università di Padova
Legnaro (PD), Italia


MAIN : : Hormones to Control Reproduction
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27